Citations

Clear

421 citation(s) found for "Short, C".

Short bowel syndrome–associated intestinal failure patient experience: A mixed‐method study leveraging an online patient community
Feldman, Josh , Gower, Megan, Kirby, Michelle, Terreri, Brian , Mundi, Manpreet S. , Feldman, Josh , Mundi, Manpreet S , Chen, Brian , McCue, Maggie

Mayo Clinic

Nutrition in Clinical Practice | August 7, 2025 | Volume: 40 | Issue: 5 | Pages: 1115-1124

10.1002/ncp.70002 | PMID 40772483 Get It

Abstract Background Patients with short bowel syndrome–associated intestinal failure (SBS‐IF) require complex, personalized, and multidisciplinary care; however, there are disparities in access. This study measured the impact of unmet needs and treatment burden among patients and their caregivers. Methods This cross‐sectional, mixed‐method study included US adults self‐reporting SBS‐IF and receiving home parenteral nutrition for ≥6 months and their caregivers. One‐hour interviews informed the development of a 30‐min survey administered to participants from an online health community. Results Among 68 patients, the mean age was 42 years, 79% were female, and 88% were White. Most of the 16 caregivers were female (69%), and younger than 45 years (69%). Of 32 patients (47%) receiving care from an SBS specialist, only 19 (59%) were referred after diagnosis; in 58% of these, referral occurred >6 months after diagnosis. Depression was reported in 44 patients (65%), with 54% not receiving professional mental health care. Financial concerns were common, with 44 patients (65%) unable to work and 40 patients (59%) reporting annual household income of <$50,000. Of 32 patients reporting difficulty paying medical bills, 22 (32%) could not fill prescriptions and 19 (28%) canceled/delayed healthcare provider visits. Social determinant of health challenges were reported by 44 patients (65%). Caregivers' responsibilities impacted their ability to work (50%) and future outlook (63%). Conclusion Patients with SBS‐IF face difficulties accessing specialized healthcare, and are at risk of adverse healthcare outcomes, financial hardships, and poor quality of life. Mental health and work/financial issues were common among both patients and caregivers.
The Impact of Frailty on Short‐Term Outcomes After Surgery for Zenker Diverticulum
Bass, Elisa , Lott, David G. , Zheng, Melissa , Lott, David G

Mayo Clinic

Otolaryngology–Head and Neck Surgery | July 29, 2025 | Volume: 173 | Issue: 4 | Pages: 947-953

10.1002/ohn.1367 | PMID 40728072 Get It

Abstract Objective Determine relationship between frailty and hospital mortality, length of stay, cost, and medical and surgical complications in Zenker diverticulum surgery. Study Design Retrospective cross‐sectional. Setting National database. Methods Data from the National Inpatient Sample for 712 patients who underwent surgery for Zenker diverticulum 2016 to 2021 were analyzed using multivariate regressions. Frailty was defined as at least 1 frailty‐defining diagnosis from the Johns Hopkins ACG® Frailty Indicator. Elixhauser Comorbidity Index was calculated to quantify comorbidity burden. Results 12.2% of patients were identified as frail, 77.0% of whom had a weight loss or malnutrition diagnosis. Frailty predicted increased length of stay (mean, 4.09 days [95% CI: 2.98‐5.20]) and increased costs (mean, $10,500.36 [95% CI: $6885.76‐$14,114.95]). Frail patients were more likely to have medical complications compared to non‐frail patients (OR = 2.84 [95% CI: 1.66‐4.84]). Elixhauser Comorbidity Index was predictive of hospital mortality (OR = 1.78 [95% CI: 1.27‐2.51]) and likelihood of endoscopic surgical complications (OR = 1.25 [95% CI: 1.05‐1.47]), but frailty was not predictive of either. Conclusion Frailty is not associated with increased risk of surgical complications or mortality and is not an absolute contraindication to Zenker diverticulum surgery. Frailty predicts length of stay, costs, and medical complications in Zenker diverticulum surgery and should be used with comorbidity to stratify patient risk for surgery. Prospective studies involving frail patients could help develop a standardized method for assessing surgical fitness, potentially expanding treatment options and improving outcomes for this population. Level of Evidence 2.
Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Wen, Patrick Y. , Lee, Eudocia Q. , Khasraw, Mustafa , Rahman, Rifaquat , Platten, Michael , Lim, Michael , Verhaak, Roel G.W. , Albert, Nathalie L. , Schiff, David , Ostrom, Quinn T. , Aldape, Kenneth , Batchelor, Tracy T. , Chiocca, E. Antonio, DeGroot, John, French, Pim J. , Hegi, Monika E. , Lassman, Andrew B. , Mellinghoff, Ingo K. , Minniti, Giuseppe, Taphoorn, Martin , Weiss, von Deimling, Tobias, Zadeh, Gelareh , Reardon, David A. , Chang, Susan M. , Short, Susan , Weller, Michael , Touat, Mehdi , Khasraw, Mustafa , Platten, Michael , Winkler, Frank , Verhaak, Roel Gw , Albert, Nathalie L , Tonn, Joerg-Christian , Barnholtz-Sloan, Jill S , Cloughesy, Timothy F , French, Pim J , Galanis, Evanthia , Galldiks, Norbert , Mellinghoff, Ingo K , Roth, Patrick , Sanson, Marc , Wick, Wolfgang , Reardon, David A , Short, Susan C , Ostrom, Quinn T , Wen, Patrick Yung , Horbinski, Craig , Huang, Raymond Y. , Ahluwalia, Manmeet S. , Barnholtz‐Sloan, Jill S. , Bindra, Ranjit S. , Cloughesy, Timothy F. , Galanis, Evanthia , Gilbert, Mark R. , Rhun, Émilie Le , Mehta, Minesh P. , Roth, Patrick , Sanson, Marc , Weiss, von Deimling, Tobias, Wick, Wolfgang , Bent, Martin J. van den , Preusser, Matthias

Mayo Clinic

Neuro-Oncology | July 22, 2025 | Volume: 27 | Issue: 11 | Pages: 2751-2788

10.1093/neuonc/noaf177 | PMID 40827022 Get It

Abstract Glioblastoma is the most common type of malignant primary brain tumor and a major cause of morbidity and mortality. In 2021, the World Health Organization updated the classification of Central Nervous System (CNS) tumors to restrict glioblastomas to isocitrate dehydrogenase-wildtype (IDHwt) tumors, improving understanding of the prognosis and optimal therapy for these tumors. This revision also enables more homogeneous populations of patients to be enrolled in clinical trials, facilitating the evaluation of novel therapies. In this updated consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of patients with glioblastoma is discussed. In addition, novel therapies such as immunotherapies, viral therapies, targeted molecular therapies, theranostics, and antibody–drug conjugates will be reviewed, as well as the current challenges and future directions for research.
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia
Montalban‐Bravo, Guillermo , Loghavi, Sanam , Li, Ziyi , Chien, Kelly S. , Kanagal‐Shamanna, Rashmi , Natu, Anuya , Gurney, Mark E. , Bazinet, Alexandre , Sasaki, Koji , Kadia, Tapan M. , Ravandi, Farhad, Pemmaraju, Naveen , Finke, Christy M. , Al‐Kali, Aref , Gangat, Naseema , Mangaonkar, Abhishek A. , Bueso‐Ramos, Carlos E. , Tefferi, Ayalew, Kantarjian, H., Garcia‐Manero, Guillermo , Patnaik, Mrinal M. , Kantarjian, Hagop M. , Chien, Kelly , Gurney, Mark , Sasaki, Koji , DiNardo, Courtney , Daver, Naval , Short, Nicholas , Pemmaraju, Naveen , Issa, Ghayas , Al-Kali, Aref , Csizmar, Clifford , Gangat, Naseema , Patnaik, Mrinal , Loghavi, Sanam , Kanagal-Shamanna, Rashmi , Kantarjian, Hagop , Bataller, Alex , Hammond, Danielle , Borthakur, Gautam , Swaminathan, Mahesh , DiNardo, Courtney D. , Ravandi, Farhad , Daver, Naval , Short, Nicholas J. , Lasho, Terra L. , Csizmar, Clifford M. , Alkhateeb, Hassan B. , Tefferi, Ayalew

Mayo Clinic

Blood Advances | July 11, 2025 | Volume: 9 | Issue: 19 | Pages: 5105-5117

10.1182/bloodadvances.2025016529 | PMID 40644618 Get It

Abstract RAS pathway (RASp) mutations induce proliferative features, and promote transformation in chronic myelomonocytic leukemia (CMML). However, the unique clonal landscape and hierarchy of distinct RASp mutations remain unexplored. To characterize the landscape, architecture, and implications of unique RASp mutations in CMML, we evaluated a cohort of 814 patients with CMML. We identified 461 RASp mutations among 342 patients (42%). N/KRAS and CBL mutations were the most common, frequently involved the P-loop or RING domains, respectively, and frequently appeared as dominant events (63% and 65%, respectively). BRAF, NF1, and PTPN11 mutations spanned throughout the gene structure, and frequently appeared as subclonal events (75%, 64%, and 59%, respectively). CBL mutations frequently occurred in codominance with SRSF2 and multihit TET2, and were enriched for KIT mutations. PTPN11 mutations more frequently co-occurred with SETBP1 and DNMT3A mutations, and were infrequently codominant with TET2 or ASXL1. RASp mutations predicted for shorter overall survival (hazard ratio [HR], 1.55; 95% confidence interval [CI], 1.15-2.07; P = .0075) and leukemia-free survival (LFS; HR, 1.67; 95% CI, 1.26-2.20; P = .0011), influenced outcomes of myelodysplastic and TET2 mutant CMML, and cooperated with IDH2 and RUNX1 mutations to induce shorter LFS. These data set the bases for refined genomic classifications of CMML, and underscore the need to develop RAS-directed therapies for patients with CMML.
Revisiting Centiloids using AI
Bourgeat, Pierrick , Xia, Ying , Feizpour, Azadeh , Zisis, Georgios , Goyal, Manu S. , Tosun, Duygu , Short, C, Adam, Robert , Robertson, Joanne, Park, Denise C. , Farrar, Gill , Bollack, Ariane , Landau, Susan , Koeppe, Robert, Morris, John, Weiner, Michael, Villemagne, Victor L. , Masters, Colin, Doré, Vincent , Xia, Ying , Feizpour, Azadeh , Goyal, Manu , Tosun, Duygu , Benzinger, Tammie L S , LaMontagne, Pamela , Sperling, Reisa Anne , O'Bryant, Sid , Johnson, Sterling C. , Jack, Clifford R , Schwarz, Christopher G , Park, Denise C , Collij, Lyduine , Rowe, Christopher Cleon , Doré, Vincent , Bourgeat, Pierrick , Fripp, Jürgen , Lebrat, Léo , Cox, Timothy O. , Gillman, Ashley , Benzinger, Tammie L.S. , Breakspear, Michael J , Lupton, Michelle K. , Short, Cathy, O’Bryant, Sid E. , Jack, Clifford R. , Schwarz, Christopher G. , Barkhof, Frederik , Masters, Colin

Mayo Clinic

No container title available | July 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7015694/v1 | PMID 40671806 Get It

Abstract The Centiloid scale is the standard for Amyloid (Aβ) PET quantification, widely used in research, clinical settings, and trial stratification. However, variability between tracers and scanners remains a challenge. This study introduces DeepSUVR, a deep learning method to correct Centiloid quantification, by penalising implausible longitudinal trajectories during training. The model was trained using data from 2,098 participants (6,762 Aβ PET scans) in AIBL/ADNI and validated using 15,806 Aβ PET scans from 10,543 participants across 10 external datasets. DeepSUVR increased correlation between tracers, and reduced variability in the Aβ-negatives. It showed the strongest association with cognition, highest AUC against visual reads and best longitudinal consistency between studies. DeepSUVR also increased the effect size for detecting lower Centiloid increase per year in the A4 study. DeepSUVR advances Aβ PET quantification, outperforming standard approaches, which is particularly important for consistent decision making and to detect subtle and early changes in clinical interventions.
Short‐Term Efficacy of Biologics in Recalcitrant Allergic Fungal Rhinosinusitis: A Systematic Review and Meta‐analysis
Im, Yeon Hee , Stybayeva, Gulnaz , Hwang, Se Hwan , Stybayeya, Gulnaz , Hwang, Se Hwan

Mayo Clinic

Otolaryngology–Head and Neck Surgery | June 24, 2025 | Volume: 173 | Issue: 4 | Pages: 840-847

10.1002/ohn.1339 | PMID 40552669 Get It

Abstract Objective Allergic fungal rhinosinusitis (AFRS) is characterized by type I immunoglobulin E (IgE)‐mediated hypersensitivity reactions to fungal antigens. This systematic review and meta‐analysis assessed the efficacy of biologics in the management of refractory AFRS. Data Sources PubMed, SCOPUS, Embase, Web of Science, and Cochrane. Review Methods Changes in Sino‐Nasal Outcome Test (SNOT)‐22 scores, endoscopic findings, serum eosinophil count, and total IgE levels were assessed in patients with refractory AFRS after receiving biologic therapy. Subgroup analyses were conducted to evaluate the individual efficacy of each biologic agent, including dupilumab, mepolizumab, and omalizumab. Results A total of 60 patients from 6 studies were analyzed. Biologics showed a significant improvement in SNOT‐22 scores (standard mean difference 1.1607 [95% CI 0.5549; 1.7664]), endoscopic scores (2.1953 [1.4181; 2.9725]), serum eosinophil count (1.1649 [0.7735; 1.5563]), and total IgE level (1.0700 [0.4052; 1.7348]). Dupilumab, mepolizumab, and omalizumab all enhanced SNOT‐22 and endoscopic scores. Additionally, dupilumab significantly reduced total IgE levels (1.2981 [0.4063; 2.1900]), whereas both dupilumab (0.9274 [0.1592; 1.6957]) and mepolizumab (1.2324 [0.9215; 1.5433]) significantly lowered the serum eosinophil counts. Conclusion The agents significantly improved nasal symptoms, laboratory findings, and endoscopic scores. These findings support the potential role of biologics as a therapeutic option for patients with AFRS who are unresponsive to conventional treatments.
Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy Consortium
Bettegowda, Chetan , Noushmehr, Houtan , Affinito, Alessandra , Ahluwalia, Manmeet S. , Ansorge, Olaf , Ayasoufi, Katayoun , Bagley, Stephen , Barnholtz‐Sloan, Jill S. , Brandsma, Dieta , Brodie, Chaya , Castro, Ana Valeria , Chang, Susan M. , Daher, Ahmad , Datta, Vineet , French, Pim J. , Golebiewska, Anna , Holdhoff, Matthias , LeBlang, Suzanne , Melin, Beatrice , Moulière, Florent , O’Leary, Claire , Robinson, Stephen , Sol, Nik , Vogelbaum, Michael A. , Walbert, Tobias , Watts, Colin , Wen, Patrick Y. , Wykes, Victoria , Yip, Stephen , Short, Susan , Barnholtz-Sloan, Jill S , Best, Myron , Brandsma, Dieta , Brüning-Richardson, Anke , Chang, Susan Marina , Condorelli, Gerolama , Daher, Ahmad , de Groot, John , French, Pim J , Galanis, Evanthia , Golebiewska, Anna , Hamerlik, Petra , Hanemann, C Oliver , Holdhoff, Matthias , Huse, Jason T. , Khasraw, Mustafa , LeBlang, Suzanne , Melin, Beatrice , Rominiyi, Ola , Roncaroli, F , Rudà, Roberta , Sol, Nik , van den Bent, Martin J , Walbert, Tobias , Watts, Colin , Weiss, Tobias , Weller, Michael , Wykes, Victoria , Yip, Stephen , Short, Susan C , Soffietti, Riccardo , Noushmehr, Houtan , Ayasoufi, Katayoun , Ahluwalia, Manmeet S , Bettegowda, Chetan , Groot, John de , Galanis, Evanthia , Hamerlik, Petra , Hanemann, C. Oliver , Khasraw, Mustafa , Rak, Janusz , Ray, Amitava, Roncaroli, Federico , Seoane, Joan , Bent, Martin J. van den , Wen, Patrick Yung , Soffietti, Riccardo

Mayo Clinic

Neuro-Oncology | June 16, 2025 | Volume: 27 | Issue: 10 | Pages: 2496-2513

10.1093/neuonc/noaf140 | PMID 40884415 Get It

Abstract This review explores the pivotal role of preanalytical variables in bringing liquid biopsy approaches into the clinic for brain tumors. Preanalytical variables encompass a range of critical issues, from blood sample collection and handling to the impact of tumor heterogeneity and patient-specific factors. These variables introduce challenges such as false positives, false negatives, and variability in the analysis of tumor signals, which can hinder the diagnostic and prognostic utility of liquid biopsies. Understanding the nuances of preanalytical variables is essential for the successful implementation of liquid biopsy in clinical settings. This paper delves into strategies aimed at mitigating the influence of preanalytical variables by emphasizing the importance of standardized sample collection protocols, optimized sample processing and storage, quality control measures, and the integration of multiple liquid biopsy modalities.
The Effect of an Osseointegration Implant on Gait Kinematics for Extremely Short Transfemoral Amputees
Wilke, Benjamin K. , Spaulding, Aaron , Patel, Janki H, Pompilio, Steve, Hemmen, Geoff , Weiss, Howard D., Kaufman, Kenton R , Spaulding, Aaron , Patel, Janki H , Pompilio, Steve , Hemmen, Geoff , Weiss, Howard , Wilke, B K , Kaufman, Kenton R.

Mayo Clinic

JBJS Case Connector | June 12, 2025 | Volume: 15 | Issue: 2 | Pages: No page available

10.2106/jbjs.cc.25.00020 | PMID 40504936 Get It

Case: We present a 55-year-old woman with a very short transfemoral amputation who underwent osseointegration. We compared gait analyses before and following osseointegration, demonstrating improvements in kinematics. At follow-up, the patient wore the prosthetic for 16 hours and averaged 10,000 steps daily. She achieved her goal of walking the beach with her prosthetic limb and often traveled without an assistive device. Conclusion: This case study of a patient with a very short transfemoral amputation demonstrated continued improvements in gait and significantly increased prosthetic use over time.
Contemporary Biology, Management, and Outcomes of Renal Medullary Carcinoma in Children and Adults: A Pediatric Surgical Oncology Research Collaborative Study
Beckhorn, Catherine B , Malek, Marcus M. , Lovvorn, Harold N. , McKay, Katlyn G. , Kontchou, Nelly‐Ange T. , Kastenberg, Zachary J. , Hoyt, David , Roach, Jonathan P. , Myers, Emily K. , Cost, Nicholas G. , Mullapudi, Bhargava , Marchese, Charles R. , Jensen, Amanda , Lundstedt, John, Brungardt, Joseph G. , Davidoff, Andrew M. , Piché, Nelson , Craig, Brian T. , Schuh, Jennifer M , Cromeens, Barrett P., Castle, Shannon L. , Mello, Kathryn Bandeira de, Short, Joshua , Petroze, Robin T. , Rajaval, Shay, Thompson, Grace R., Fialkowski, Elizabeth , Martchenke, Nathan, Rich, Barrie S. , Glick, Richard D. , Doyle, Kathleen , Abril, Paige, Seemann, Natashia M. , Davidson, Jacob B., Wilson, Claire A. , Joshi, Devashish , Stellon, Michael , Newman, Erika A. , Hammoud, Maya M. , Williams, Keyonna M , Grant, Christa N. , Gorgy, Merit , Polites, Stephanie F. , Debertin, Julia , Cameron, Danielle B. , Stetson, Alyssa , Lee, William G. , Barkhordar, Aaron, Austin, Mary T. , Coakley, Brian A. , Kahan, Anastasia M , Murphy, Joseph T., Pitonak, Michael, Boehmer, Chloé , Tracy, Elisabeth T. , Kastenberg, Zachary J , Hoyt, David W , Cost, Nicholas G , Marchese, Charles R , Lautz, Timothy , Lundstedt, John , Brungardt, Joseph G , Talbot, Lindsay J , Murphy, Andrew J , Aldrink, Jennifer H , Piche, Nelson , Mannava, Sindhu V , Fialkowski, Elizabeth A , Rich, Barrie S , Seemann, Natashia M , Stellon, Michael , Dimmer, Alexandra M , Williams, Keyonna , Barkhordar, Aaron , Beckhorn, Catherine , Tracy, Elisabeth T , Malek, Marcus M , Kahan, Anastasia Morgan , Leraas, Harold J. , Lautz, Timothy B. , Carter, Michela M. , Dasgupta, Roshni , Murphy, Andrew J. , Aldrink, Jennifer H. , Mansfield, Sara A. , Lal, Dave R. , López, Adriana , Mattei, Peter , Rothstein, David H. , Fowler, Kathryn L. , Brown, Erin G. , Abril, Paige, Rinehardt, Hannah , Le, Hau D. , Ahmed, Tamer, Kim, Eugene S. , Pitonak, M.

Mayo Clinic

Pediatric Blood & Cancer | May 21, 2025 | Volume: 72 | Issue: 8 | Pages: No page available

10.1002/pbc.31774 | PMID 40394815 Get It

ABSTRACTBackgroundRenal medullary carcinoma (RMC) is an aggressive tumor associated with sickle cell trait. Despite treatment advances for other rare renal tumors, RMC survival remains poor. We aimed to describe the contemporary management and survival of children and adults with RMC.ProcedureIn this multicenter retrospective cohort study, Pediatric Surgical Oncology Research Collaborative sites searched their databases for patients diagnosed with RMC (2000–2022). Descriptive statistics were calculated and survival analyses performed using Kaplan–Meier and Cox regression.ResultsThirty‐four patients with RMC were identified. Median age was 19 years (IQR: 15–28; range: 7–52). Most were male (24/34; 71%), Black (27/32; 84%), had sickle cell trait or disease (30/33; 91%), presented with metastatic disease (27/34; 79%), and were symptomatic at presentation (32/34; 94%). Median overall survival (OS) was 24 months from diagnosis (16 months for children, 28 months for adults, p = 0.6). Receipt of platinum‐based chemotherapy (23/34; 68%) was associated with significantly higher OS than other regimens (35 vs. 5 months, p < 0.001). Nephrectomy (24/34; 71%) was associated with significantly improved OS compared with non‐operative management (34 vs. 7 months, p = 0.001). Immunotherapy, targeted therapy, or radiation therapy were not associated with significant differences in OS, nor were age, sex, race, sickle cell status, SMARCB1/INI‐1, stage, nephrectomy approach, retroperitoneal lymph node dissection, gross residual disease, margins, or tumor size.ConclusionsRMC survival remains poor despite newer therapies. Nephrectomy and platinum‐based chemotherapy should be considered in locally advanced and metastatic disease. Coordinated international cooperative group studies are needed to meaningfully improve RMC survival.